This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

FLULAVAL Logo

Prescribing Information

Coding for FLULAVAL

Here you’ll find vaccine product codes and some common administration codes associated with immunization using FLULAVAL (a trivalent influenza vaccine). Select another vaccine here.

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of the International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Description: FLULAVAL is supplied in 0.5-mL single-dose prefilled Tip-Lok syringes (packaged without needles)1

Dosage: 0.5 mL1

Coding for FLULAVAL

CPT Code

90656

ICD-10-CM Code2*

Z23
MVX Code3 IDB
CVX Code4 140

NDCs† (Syringe in package of 10)

2024/2025 Outer Carton

NDC 19515-810-52

2024/2025 Syringe

NDC 19515-810-41
Tip

Tip

To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.

FLULAVAL CPT Code – Immunization Administration Codes5‡

Medicare HCPCS Level II Code6

G0008:

Administration of influenza virus vaccine

Immunization administration through 18 years of age with counseling by physician or other qualified healthcare professional.

90460:

Immunization administration via any route, first vaccine/toxoid component 

Immunization administration of any vaccine for a patient through 18 years of age that is not accompanied by counseling, or for administration of vaccines to patients over 18 years of age.

90471:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)

+90472:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), each additional vaccine (single or combination vaccine/toxoid)
(List separately in addition to code for primary procedure)

Tip

Tip

If reporting multiple vaccine administrations given to a patient through age 18 on the same date along with counseling by a qualified healthcare professional, report one administration code (90460) for each vaccine administered.7

Diagnosis Codes

Z23 is the ICD-10-CM code used when reporting an encounter for immunization for all vaccines given within the encounter. In some instances, additional ICD-10-CM coding may be needed. 

See all code types

GSK Codes Summary Sheet

Get a PDF of the most current CPT, CVX, MVX, and NDC codes for GSK vaccines.

Download

Questions?

Find answers to frequently asked questions, along with additional resources, to guide you to the information you need.

Get help

  •   *ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.2
  •   †Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.8 For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11.
  •    ‡Adapted from the American Medical Association, CPT 2023 Professional Edition, Current Procedural Terminology (CPT), 2023.

References:

  1. Prescribing Information for FLULAVAL.
  2. 2023 ICD-10-CM official guidelines for coding and reporting. Centers for Medicare and Medicaid Services. Updated April 1, 2023. Accessed February 7, 2024. https://www.cms.gov/files/document/fy-2023-icd-10-cm-coding-guidelines-updated-01/11/2023.pdf
  3. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. Centers for Disease Control and Prevention. Accessed February 7, 2024. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx
  4. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Centers for Disease Control and Prevention. Accessed February 7, 2024. https://www2a.cdc.gov/vaccines/IIS/IISStandards/downloads/cvx_list.pdf
  5. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. American Medical Association. Updated December 28, 2023. Accessed February 7, 2024. https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf
  6. HCPCS quarterly update. Centers for Medicare and Medicaid Services. HCPCS April 2024 index. Updated March 7, 2024. Accessed March 15, 2024. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update
  7. Bright futures coding for pediatric preventive care 2022. American Academy of Pediatrics. Accessed February 7, 2024. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf
  8. Office injectable guidelines, National Drug Code (NDC) pricing and filing tips. Humana Military. Accessed February 7, 2024. https://www.humanamilitary.com/provider/claims/injectables#nucleustabs-ee21c6fea3-item-098209c56a-tab

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

Indication for FLULAVAL

FLULAVAL is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is approved for use in persons aged 6 months and older.

Important Safety Information for FLULAVAL

  • Do not administer FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL. Procedures should be in place to avoid injury from fainting
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLULAVAL
  • If FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • The most common (≥10%) solicited local adverse reactions with FLULAVAL in adults were pain (51%), redness (13%), and swelling (11%), and the most common solicited systemic adverse reactions were fatigue (20%), headache (18%), and muscle aches/arthralgia (18%). In children aged 3 through 17 years, the most common (≥10%) solicited local adverse reaction was pain (56%). In children aged 3 through 4 years, the most common (≥10%) solicited systemic adverse reactions were irritability (25%), drowsiness (19%), and loss of appetite (16%). In children aged 5 through 17 years, the most common (≥10%) solicited systemic adverse reactions were muscle aches (24%), headache (17%), and fatigue (17%). In children aged 6 through 35 months who received FLULAVAL QUADRIVALENT, the most common (≥10%) solicited local adverse reaction was pain (40%), and the most common solicited systemic adverse reactions were irritability (49%), drowsiness (37%), and loss of appetite (29%)
  • Vaccination with FLULAVAL may not result in protection of all vaccine recipients

Please see full Prescribing Information for FLULAVAL.